» Articles » PMID: 24518506

Comparable Efficacy of Low- Versus High-dose Induction Corticosteroid Treatment in Autoimmune Pancreatitis

Abstract

Objective: The objective of this study was to compare efficacy of high versus low doses of prednisone for induction of remission in autoimmune pancreatitis (AIP).

Methods: This is a retrospective, multicenter study including patients diagnosed with AIP between May 1992 and August 2011. Clinical, laboratory and imaging findings were assessed before treatment and at 1, 3, and 6 months after starting treatment.

Results: A total of 65 patients (57 males; median age, 63 years) were treated with an initial low dose (10-20 mg/d, n = 14), a medium dose (30 mg/d, n = 15), or a high dose (40-60 mg/d, n = 36) of prednisone. There were no significant differences in baseline characteristics between the treatment groups including age, presenting symptoms and laboratory results. During a follow-up period of 6 months, in nearly all patients, symptoms (jaundice, weight loss) resolved completely. After 6 months, treatment response with respect to symptomatic, radiological, and laboratory improvement was comparable for the different dosage groups.

Conclusions: Response to therapy was comparable for AIP patients treated with doses of prednisone in the range of 10 to 60 mg/d. A prospective trial should be conducted to confirm efficacy of lower-dose prednisone treatment.

Citing Articles

Update on Autoimmune Pancreatitis and IgG4-Related Disease.

Lanzillotta M, Vujasinovic M, Lohr J, Della Torre E United European Gastroenterol J. 2024; 13(1):107-115.

PMID: 39707927 PMC: 11866317. DOI: 10.1002/ueg2.12738.


Challenges for clinicians treating autoimmune pancreatitis: Current perspectives.

Kim S, Lee Y, Chon H World J Clin Cases. 2023; 11(1):30-46.

PMID: 36687190 PMC: 9846983. DOI: 10.12998/wjcc.v11.i1.30.


Autoimmune Pancreatitis Masquerading as Pancreatic Cancer: A Case Report and Literature Review.

Agarwal K, Jassal R, Browne A, Hossain M, Akhtar R Cureus. 2022; 14(2):e21900.

PMID: 35265424 PMC: 8898479. DOI: 10.7759/cureus.21900.


PrescrAIP: A Pan-European Study on Current Treatment Regimens of Auto-Immune Pancreatitis.

Lanzillotta M, Vinge-Holmquist O, Overbeek K, Poulsen J, Demirci A, Macinga P Front Med (Lausanne). 2020; 7:408.

PMID: 32850908 PMC: 7419461. DOI: 10.3389/fmed.2020.00408.


European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations.

Lohr J, Beuers U, Vujasinovic M, Alvaro D, Frokjaer J, Buttgereit F United European Gastroenterol J. 2020; 8(6):637-666.

PMID: 32552502 PMC: 7437085. DOI: 10.1177/2050640620934911.